Physician profile
Matthew Nelson
NPI 1760724132
$4,165.21
in general payments reported to CMS, 2019-2025
17 companies · $982 in 2025
The $982 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $135 · 2021: $120 · 2022: $714 · 2023: $631 · 2024: $1,345 · 2025: $982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,943 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,943.20 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,755.85 | 2020-2025 | |
| Boston Scientific Corporation | $736.76 | 2023-2025 | Exalt Model D, Agile Esophageal, Acquire |
| Olympus America INC. | $589.87 | 2021-2025 | Disposable Emr Kit, Endoclot Phs, Single Use Repositionable Clip |
| Takeda Pharmaceuticals U.S.A., INC. | $236.92 | 2020-2025 | Entyvio, Eohilia |
| Pfizer INC. | $180.07 | 2019-2022 | |
| Medtronic, INC. | $164.76 | 2022 | |
| Novo Nordisk INC | $120.68 | 2025 | Wegovy |
| Allergan, INC. | $119.52 | 2019 | |
| Lilly USA, LLC | $62.65 | 2024-2025 | Omvoh |
| Janssen Biotech, INC. | $43.72 | 2023-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.32 | 2022-2024 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $29.68 | 2024 | Dupixent |
| Madrigal Pharmaceuticals | $22.04 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $18.66 | 2024 | Bylvay |
| Capsovision, INC. | $15.82 | 2025 | Capsocam Plus |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $15.13 | 2023 | |
| Celgene Corporation | $12.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.